The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
<0> Teva Pharmaceutical Industries Ltd.IR:United States 215-591-8912or215-591-3033orIsrael 972 (3) 926-7656orPR:Israel 972 (3) 926-7687orUnited States 215-591-8974or215-284-0213 </0> Teva ...
JERUSALEM--(BUSINESS WIRE)--Jan. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental ...
AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and ...
Copaxone (glatiramer) is a prescription drug that’s used in adults to treat certain types of multiple sclerosis and clinically isolated syndrome. Copaxone comes as a liquid solution that you’ll inject ...
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced positive results from a study assessing a new lower-volume injection of Copaxone ® (glatiramer acetate) ...
Glatiramer acetate (Copaxone) is an injectable drug that treats relapsing forms of multiple sclerosis in adults. It’s a man-made version of a protein similar to one found in myelin, an insulating ...
Copaxone is a prescription drug used to treat different types of multiple sclerosis (MS) in adults. It can cause side effects that range from mild to serious, including injection site reactions, ...
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY® (fremanezumab) and the burden of migraine in Europe will be ...
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office’s (EPO) Opposition Division upheld patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback